Parallel evolutions of the growth rate of newly diagnosed HIV cases and the proportion of potentially infective patients in Cayenne French Guiana: Should HAART be used to curb the epidemic?

Public Health

Volumn 123, Issue 8, 2009, Pages 573-574

  Nacher, M ^a,b   Vantilcke, V ^a   Huber, F ^a   El Guedj, M ^a   Vaz, T ^a   Magnien, C ^a   Djossou, F ^a   Mahamat, A ^a   Dabis, F ^c   Couppie P ^a  

^a CENTRE HOSPITALIER DE CAYENNE   (French Guiana)

^b UNIVERSITÉ DES ANTILLES ET DE LA GUYANE   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

DISEASE PREVALENCE; DISEASE TRANSMISSION; DISEASE TREATMENT; EPIDEMIC; GROWTH RATE; HUMAN IMMUNODEFICIENCY VIRUS;

ARTICLE; DEATH; DRUG EFFICACY; EARLY INTERVENTION; EPIDEMIC; FRENCH GUIANA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; POVERTY; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SOCIAL DISCRIMINATION; STIGMA; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE OUTBREAKS; FRENCH GUIANA; HIV INFECTIONS; HIV-1; HUMANS; RISK; SOCIOECONOMIC FACTORS; VIRAL LOAD;

CAYENNE; FRENCH GUIANA; SOUTH AMERICA;

EID: 69949104389     PISSN: 00333506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.puhe.2009.06.007     Document Type: Article

References (11)

1. Montaner J.S., Hogg R., Wood E., Kerr T., Tyndall M., Levy A.R., et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 9534 (2006) 531-536
2. Quinn T.C., Wawer M.J., Sewankambo N., Serwadda D., Li C., Wabwire-Mangen F., et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 342 (2000) 921-929
3. Vernazza P., Hirschel B., Bernasconi E., and Flepp M. HIV-positive individuals without additional sexually transmitted diseases (STD) and on effective anti-retroviral therapy are sexually non-infectious. Schweizerische Ärztezeitung/Bulletin des médecins suisses/Bollettino dei medici svizzeri 89 (2008) 5
4. Institut national de veille sanitaire HIV databases 2008. Available from:. http://www.invs.sante.fr/bdd/index.htm
5. Nacher M., El Guedj M., Vaz T., Nasser V., Randrianjohany A., Alvarez F., et al. Risk factors for late HIV diagnosis in French Guiana. AIDS 19 (2005) 727-729
6. Masse V., Dray-Spira R., Spire B., Schmaus A., and Lert F. Sex life and prevention among heterosexuals living with HIV/AIDS in the French Antilles and French Guiana: results from the ANRS-VESPA study 2003. BEH 46/47 (2005) 243-244
7. Halfen S., Fiennes K., Ung B., and Grémy I. Knowledge, beliefs and attitudes on HIV/AIDS in the French Antilles and French Guiana in 2004 (2005), ORS Ile de France-ANRS
8. Moore R.D., and Keruly J.C. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 44 (2007) 441-446
9. Kolson D.L., and Gonzalez-Scarano F. HIV and HIV dementia. J Clin Invest 106 (2000) 11-13
10. Hammer S.M., Eron Jr. J.J., Reiss P., Schooley R.T., Thompson M.A., Walmsley S., et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300 (2008) 555-570
11. Fang C.T., Hsu H.M., Twu S.J., Chen M.Y., Chang Y.Y., Hwang J.S., et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 190 (2004) 879-885